Serelaxin

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Serelaxin
Accession Number
DB05794
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Other protein based therapies
Description

Recombinant human relaxin is a hormone produced during pregnancy that facilitates the birth process by causing a softening and lengthening of the cervix and the pubic symphysis (the place where the pubic bones come together).It is a heterodimer protein secreted by the corpus luteum and placenta during pregnancy.

Protein chemical formula
C6H11MgO7
Protein average weight
219.4523 Da
Sequences
Not Available
Synonyms
  • Human relaxin 2 (relaxin h2)
  • Human relaxin recombinant
  • Recombinant human relaxin
Categories
UNII
W0122B976Y
CAS number
99489-94-8

Pharmacology

Indication

Investigated for use/treatment in cardiovascular disorders, congestive heart failure, infertility, peripheral vascular disease, and scleroderma.

Pharmacodynamics
Not Available
Mechanism of action

Recombinant human relaxin inhibits contractions of the uterus and may play a role in timing of delivery. Relaxin works by simultaneously cutting collagen production and increasing collagen breakdown.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
  1. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP: Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology. 2006 Nov;147(11):5126-31. Epub 2006 Jul 27. [PubMed:16873529]
  2. Nistri S, Cinci L, Perna AM, Masini E, Mastroianni R, Bani D: Relaxin induces mast cell inhibition and reduces ventricular arrhythmias in a swine model of acute myocardial infarction. Pharmacol Res. 2008 Jan;57(1):43-8. Epub 2007 Nov 9. [PubMed:18068999]
External Links
PubChem Substance
347910234
Wikipedia
Relaxin
ATC Codes
C01DX21 — Serelaxin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceChronic Renal Failure (CRF) / End-Stage Renal Disease (ESRD)1
1SuspendedTreatmentProphylaxis of preeclampsia1
2CompletedNot AvailableChronic Heart Failure (CHF)1
2CompletedTreatmentAcute Heart Failure (AHF)1
2CompletedTreatmentCompensated Cirrhosis and Portal Hypertension1
2CompletedTreatmentCoronary Artery Disease1
2CompletedTreatmentInduction of Labour1
2CompletedTreatmentLiver Cirrhosis / Portal Hypertension1
2TerminatedTreatmentAcute Heart Failure (AHF)1
2TerminatedTreatmentChronic Heart Failure (CHF)1
2TerminatedTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentAcute Heart Failure (AHF)1
3TerminatedTreatmentAcute Heart Failure (AHF)1
3TerminatedTreatmentAcute Heart Failure (AHF) / Mild-to-moderate Renal Impairment / Systolic Blood Pressure > or = 125 mm Hg1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on November 18, 2007 11:27 / Updated on June 04, 2019 06:19